Rubicon Research Ltd., a specialty pharmaceutical company focusing on drug-device combinations and regulated market formulations, is set to launch its Initial Public Offering (IPO) on October 9, 2025. The IPO aims to raise ₹1,377.5 crore, comprising a fresh issue of ₹500 crore and an offer for sale (OFS) of ₹877.5 crore by promoter General Atlantic Singapore RR Pte Ltd. The subscription window will close on October 13, with listing expected on BSE and NSE on October 16. Proceeds will be used for debt repayment, strategic acquisitions, and general corporate purposes, signaling strong growth ambitions.
IPO Structure and Pricing
Rubicon Research’s IPO is a book-built issue with a price band of ₹461–₹485 per share. The offering consists of a fresh issue of ₹500 crore and an OFS of ₹877.5 crore by General Atlantic Singapore RR Pte Ltd, which currently holds a 52.15% stake. Allocation among investors is divided as 75% for Qualified Institutional Buyers (QIBs), 15% for Non-Institutional Investors (NIIs), and 10% for Retail Individual Investors (RIIs).
Financial Performance
For the fiscal year ending March 2025, Rubicon Research reported a profit of ₹134.4 crore, up 47.6% from ₹91 crore in the previous year. Revenue surged 50.4% to ₹1,284.3 crore from ₹853.9 crore, driven by strong demand for specialty products and drug-device combinations in regulated markets, particularly the United States. This financial growth underscores the company’s market positioning and potential for investor returns.
Utilization of IPO Proceeds
Debt Repayment: Approximately ₹310 crore will be allocated to repay outstanding borrowings, which totaled ₹495.8 crore as of June 2025.
Strategic Acquisitions: Funds will support inorganic growth and strategic business expansions.
General Corporate Purposes: Remaining proceeds will be used for general corporate initiatives and operational flexibility.
Key Dates
Anchor Investor Bidding: October 8, 2025
IPO Opening Date: October 9, 2025
IPO Closing Date: October 13, 2025
Basis of Allotment: October 14, 2025
Refunds Initiated & Shares Credited: October 15, 2025
Listing on BSE/NSE: October 16, 2025
Investment Insights
Rubicon Research’s robust financials, strategic focus on regulated markets, and plans for debt reduction and growth through acquisitions position the company as an attractive IPO candidate. Investors should weigh the company’s strong performance and growth potential against market conditions and risk factors before participating.
Comments